Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.

Abstract: Water electrolysis systems that operate at intermediate temperature (i.e., between about 100° C. and about 300° C.) are described. At least some aspects of the present disclosure relate to proton exchange membrane steam electrolysis (PEMSE) systems including a polymer electrolyte comprising at least one phosphorus atom. In at some examples, the polymer electrolyte my comprise phosphonic acid.

Abstract: A memory device includes a first field effect transistor (FET) stack on a first bottom source/drain region, which includes a first vertical transport field effect transistor (VTFET) device between a second VTFET device and the first source/drain region, and a second FET stack on a second bottom source/drain region, which includes a third VTFET device between a fourth VTFET device and the bottom source/drain region. The memory device includes a third FET stack on a third bottom source/drain region, which includes a fifth VTFET between a sixth VTFET and the third source/drain region, which is laterally adjacent to the first and second source/drain regions. The memory device includes a first electrical connection interconnecting a gate structure of the third VTFET with a gate structure of the fifth VTFET, and a second electrical connection interconnecting a gate structure of the second VTFET with a gate structure of the sixth VTFET.

Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).

Abstract: A thermally sensitive ionic redox transistor comprises a channel, a reservoir layer, and an electrolyte layer disposed between the channel and the reservoir layer. A conductance of the channel is varied by changing concentration of ions in the channel layer. The electrolyte layer is configured to undergo a state change at a state transition temperature. Below the state transition temperature, ions in the electrolyte layer are substantially immobile. Above the state transition temperature, ions can move freely between the reservoir layer and the channel across the electrolyte layer in response to a voltage being applied between the channel and the reservoir layer. When the device is cooled below the state transition temperature or temperature range, the ions are trapped in one or more of the layers because the electrolyte layer loses its ionic conductivity. A state of the redox transistor can be read by measuring the conductance of the channel.

Abstract: A semiconductor structure includes a first field-effect transistor having a first back side source/drain contact, a second back side source/drain contact, and a first power line and a first signal line each connected to the first back side source/drain contact and the second back side source/drain contact, respectively. The semiconductor structure further includes a second field-effect transistor vertically stacked above the first field-effect transistor. The second field-effect transistor having a first front side source/drain contact, a second front side source/drain contact, and a first power line and a first signal line each connected to the first front side source/drain contact and the second front side source/drain contact, respectively.

Abstract: A method for identifying carpet materials includes receiving, by a controller coupled to an NIR spectrometer, a predetermined number of NIR measurements of a sample of the carpet material conducted over a bandwidth of a subset of a full NIR spectrum. The NIR spectrometer performs the NIR measurements under control of the controller. Also, sending the NTR measurements to a remote identification server including a spectra library of known carpet materials. The method also includes receiving a matching result from the remote identification server, sending the matching result to a remote appraisal server, and receiving an appraised value of the carpet material.

Abstract: A method for identifying carpet materials includes receiving, by a controller coupled to an NIR spectrometer, a predetermined number of NIR measurements of a sample of the carpet material conducted over a bandwidth of a subset of a full NIR spectrum. The NIR spectrometer performs the NIR measurements under control of the controller. Also, sending the NIR measurements to a remote identification server including a spectra library of known carpet materials. The method also includes receiving a matching result from the remote identification server, sending the matching result to a remote appraisal server, and receiving an appraised value of the carpet material.

Abstract: The present disclosure provides an in vitro reagent for evaluating xenobiotic metabolism in a cell culture based assay. The in vitro reagent is an admixture of metabolically competent cells and exogenous drug metabolizing enzyme co-factors follow by cryopreservation in the absence of cryopreservation agent so that the cells would be rendered permeable upon thawing due to plasma membrane disruption (while maintaining the integrity of organelles). The permeabilized plasma membranes allow ready diffusion of the exogenous cofactors into the cells to enhance the activities of cellular drug metabolizing enzymes. Addition of a xenobiotic test compound to the thawed in vitro reagent allows metabolism of the test compound by the metabolically competent cells, with metabolites readily diffusible outside the cells due to the permeabilized plasma membranes.

Abstract: The present disclosure provides an in vitro reagent for evaluating xenobiotic metabolism in a cell culture based assay. The in vitro reagent is an admixture of a cell culture medium and isolated intestinal mucosa comprising villi wherein the intestinal mucosa was eluted from a lumen of the intestine. The isolated mucosa comprises metabolically competent cells. Addition of a xenobiotic test compound to the in vitro reagent allows metabolism of the test compound by the isolated intestinal mucosa comprising villi.

Abstract: The present disclosure provides a pre-cooked egg product; a yolkless egg-white food product. The pre-cooked egg product is a natural egg-white food product cooked in a geometric shape, which does not contain an egg yolk, including an artificial or simulated egg yolk. The pre-cooked natural egg-white food product optionally contains a food additive, such as coloring or flavoring, or optionally contains an artificial inner core that is a sweet, savory, meat, plant or dairy product.

Abstract: A method is disclosed wherein human organ cells (e.g. hepatocytes) are cultured in human plasma medium (e.g., 70% to 100% human plasma) in place of the routinely used non-human plasma cell culture growth medium. This culture method allows the human organ cells to be in an environment that closely resembles that of the in vivo environment, where the cells are bathed in human plasma. Also, disclosed herein are cell culture systems containing the human organ cells and human plasma medium in a cell culture vessel. Uses of the cell culture system includes application of cultured human organ cells to evaluate test compound properties, including pharmacological, pharmacokinetic, and toxicological effects of drugs, organ disease progression, such as liver disease progression including hepatitis B infection or hepatitis C infection, or cell biology process, such as gene expression, protein synthesis or response to hormones, that can be directly translated to human in vivo.

Abstract: A dialog knowledge acquisition system includes a hardware processor, a memory, and hardware processor controlled input and output modules. The memory stores a dialog manager configured to instantiate a persistent interactive personality (PIP), and a dialog graph having linked dialog state nodes. The dialog manager receives dialog initiation data, identifies a first state node on the dialog graph corresponding to the dialog initiation data, determines a dialog interaction by the PIP based on the dialog initiation data and the first state node, and renders the dialog interaction. The dialog manager also receives feedback data corresponding to the dialog interaction, identifies a second state node based on the dialog initiation data, the dialog interaction, and the feedback data, and utilizes the dialog initiation data, the first state node, the dialog interaction, the feedback data, and the second state node to train the dialog graph.

Abstract: The present disclosure provides an in vitro reagent for evaluating xenobiotic metabolism in a cell culture based assay. The in vitro reagent is an admixture of metabolically competent cells and exogenous drug metabolizing enzyme co-factors follow by cryopreservation in the absence of cryopreservation agent so that the cells would be rendered permeable upon thawing due to plasma membrane disruption (while maintaining the integrity of organelles). The permeabilized plasma membranes allow ready diffusion of the exogenous cofactors into the cells to enhance the activities of cellular drug metabolizing enzymes. Addition of a xenobiotic test compound to the thawed in vitro reagent allows metabolism of the test compound by the metabolically competent cells, with metabolites readily diffusible outside the cells due to the permeabilized plasma membranes.

Abstract: A dialog knowledge acquisition system includes a hardware processor, a memory, and hardware processor controlled input and output modules. The memory stores a dialog manager configured to instantiate a persistent interactive personality (PIP), and a dialog graph having linked dialog state nodes. The dialog manager receives dialog initiation data, identifies a first state node on the dialog graph corresponding to the dialog initiation data, determines a dialog interaction by the PIP based on the dialog initiation data and the first state node, and renders the dialog interaction. The dialog manager also receives feedback data corresponding to the dialog interaction, identifies a second state node based on the dialog initiation data, the dialog interaction, and the feedback data, and utilizes the dialog initiation data, the first state node, the dialog interaction, the feedback data, and the second state node to train the dialog graph.

Abstract: A method of thawing cryopreserved human hepatocytes and cryopreserving the hepatocytes a second time without losing viability is described. It allows the preparation of cryopreserved human hepatocytes pooled from multiple donors by thawing the hepatocytes from the individual donors, combining the cells to form pooled hepatocytes, and recryopreserving the pooled hepatocytes. The method involves the thawing of the hepatocytes from the individual donors, maintaining the thawed hepatocytes at a low temperature that is above freezing temperature, and refreezing the thawed cells without further manipulation. The method allows the cryopreserving the human hepatocytes a second time after thawing, with viability similar to that after one single cryopreservation. This high efficiency method can be used for the preparation of highly viable pooled human hepatocytes for experimentation to minimize individual variations.

Abstract: A method of thawing cryopreserved human hepatocytes and cryopreserving the hepatocytes a second time without losing viability is described. It allows the preparation of cryopreserved human hepatocytes pooled from multiple donors by thawing the hepatocytes from the individual donors, combining the cells to form pooled hepatocytes, and recryopreserving the pooled hepatocytes. The method involves the thawing of the hepatocytes from the individual donors, maintaining the thawed hepatocytes at a low temperature that is above freezing temperature (e.g., 4° C.), and refreezing the thawed cells without further manipulation. The method allows the cryopreserving the human hepatocytes a second time after thawing, with viability similar to that after one single cryopreservation. This high efficiency method can be used for the preparation of highly viable pooled human hepatocytes for experimentation to minimize individual variations.

Abstract: A method of thawing cryopreserved human hepatocytes and cryopreserving the hepatocytes a second time without losing viability is described. It allows the preparation of cryopreserved human hepatocytes pooled from multiple donors by thawing the hepatocytes from the individual donors, combining the cells to form pooled hepatocytes, and recryopreserving the pooled hepatocytes. The method involves the thawing of the hepatocytes from the individual donors, maintaining the thawed hepatocytes at a low temperature that is above freezing temperature (e.g., 4° C.), and refreezing the thawed cells without further manipulation. The method allows the cryopreserving the human hepatocytes a second time after thawing, with viability similar to that after one single cryopreservation. This high efficiency method can be used for the preparation of highly viable pooled human hepatocytes for experimentation to minimize individual variations.

Abstract: A method is provided for identifying use of a proprietary circuit layout. A representation of a layout of a circuit is input and the locations of a set of predetermined physical features of the circuit are identified. This set of locations is then compared with a previously generated characteristic pattern file, the characteristic pattern file comprising a representation of relative locations of a set of these predetermined physical features in the proprietary circuit layout. If the set of locations matches the relative locations of the characteristic pattern file, then an output is generated indicating that use of the proprietary circuit design has been found.